Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine)

EU orphan designation number: EU/3/12/1006   
Active ingredient: Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine)
Indication: Treatment of glioma
Sponsor: Avena Therapeutics Ltd
Trinity Research and Innovation, Trinity College Dublin, Dublin 2, Ireland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/11/2012 Centralised Orphan - Designation EMA/OD/019/12 (2012)8887 of 28/11/2012